|
Jan 3
|
Pharma Stock Roundup: PFE Ends Hemophilia Deal With SGMO & More
|
|
Jan 3
|
Positive data could expand use of Novartis’ gene therapy for SMA
|
|
Dec 31
|
Novartis' Gene Therapy Meets Primary Endpoint in SMA Study
|
|
Dec 31
|
Here's Why Novartis (NVS) is a Strong Growth Stock
|
|
Dec 31
|
Novartis’ Gene Therapy Shows Promise in Treating SMA
|
|
Dec 31
|
Novartis’ Phase III spinal muscular atrophy therapy trial meets primary endpoint
|
|
Dec 30
|
Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA
|